| Primary information |
|---|
| sequence ID | Seq_2936 |
| Peptide sequence | GNTEGLQKSLAELGGHLDQQVEEF |
| CancerPDF_ID | CancerPDF_ID81, CancerPDF_ID1079, CancerPDF_ID1400, CancerPDF_ID2629, CancerPDF_ID9569, |
| PMID | 16896061,16395409,21136997,21136997,21533267 |
| Protein Name | Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV |
| UniprotKB Entry Name | APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN |
| Fluid | Serum,Serum,Serum,Plasma,Serum |
| M/Z | 2599.18,2599.18,2598.25617,2598.2562,867.1 |
| Charge | 1,1,1,1,3 |
| Mass (in Da) | 2599.25,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS |
| Quantification Technique | NA,NA,LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,0.001,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID81, CancerPDF_ID1079, CancerPDF_ID1400, CancerPDF_ID2629, CancerPDF_ID9569, |
| p-Value | 1.00E-05,NA,1.48E-04,NA,NA |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT |
| Length | 24,24,24,24,24 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,Differentially expressed between cancer vs normal,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Independent validation,Independent validation,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset,0.898,NA,NA |
| Specificity | 95% on independent dataset,NA,0.946,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,0.917,NA,NA |
| Peptide Atlas | NA |
| IEDB | |